An ambulance crew is, among other things, a rolling site of live clinical research. Three separate stories from the past few months show how much that setting now contributes to […]
- September 4, 2026
- By Daniel Molloy-Brookes
- Business
A Ban, a Gene and a Clock: Three New Ways of Understanding Caffeine
Caffeine is the most widely used psychoactive substance in the world, and it is currently the subject of three quite different strands of life sciences research. This summer, the government […]
- September 3, 2026
- By Daniel Molloy-Brookes
- Business
Down to Earth: What Gardening and Allotments Are Teaching the Life Sciences Sector
Across the UK, well over 100,000 people are currently on a waiting list for an allotment, with an average wait of around four years before a plot becomes free. That […]
- September 2, 2026
- By Daniel Molloy-Brookes
- Business
The NHS Opened Flu Jabs to Millions of Children and Pregnant Women. Here Is Why This Year’s Vaccine Was Different.
On 1 September, millions of children and pregnant women across England became eligible for their flu vaccination as the NHS began the first phase of this year’s winter immunisation programme. […]
- September 1, 2026
- By Daniel Molloy-Brookes
- Business
Field Recordings: What Festival Season Taught Life Sciences in 2026
Every summer, several million people in the UK pass through festival gates, and without quite meaning to, they leave behind an extraordinary dataset. Now that the tents have come down […]
- August 29, 2026
- By Daniel Molloy-Brookes
- Business
In at the Deep End: What Cold Water Swimming Is Teaching Life Sciences
The largest meta-analysis yet of cold-water immersion has found it does the opposite of one of its most-repeated claims, actually raising inflammation markers rather than lowering them, at least in […]
- August 28, 2026
- By Daniel Molloy-Brookes
- Business
The Evidence Behind the Playlist: What Music Therapy Is Teaching Life Sciences
Greater Manchester has become the UK’s first Centre of Excellence for Music and Dementia, backed by more than £1 million and a decade of prior research, a Shanghai hospital has […]
- August 27, 2026
- By Daniel Molloy-Brookes
- Business
Pit Lane to Patient Bay: What Formula One Teaches Life Sciences
A children’s hospital cut surgical handover errors by more than 40% after its doctors studied a Ferrari pit crew, new research has found that the cooling shirt Formula One has […]
- August 26, 2026
- By Daniel Molloy-Brookes
- Business
Cleared for Landing: How Aircraft Are Shaping Life Sciences in 2026
A small fixed-wing drone now carries organ donor blood samples across 160 miles of Missouri in under two hours, a French research team has mapped exactly when aircraft cabin air […]
- August 25, 2026
- By Daniel Molloy-Brookes
- Business
The Great Rebuild: Why Pharmaceutical Manufacturing Is Being Restructured From the Ground Up
Tariffs on branded drugs took effect on 31 July 2026 for the largest companies, with generics now on a phased tariff timeline to 2028. A biologics boom and an industrialisation […]
- August 24, 2026
- By Daniel Molloy-Brookes
- Business
The NHS Has Put Wearables at the Heart of Its Future. Now Comes the Hard Part.
England’s 10-year health plan names wearables as one of five transformative technologies that will reshape care delivery by 2035. The ambition is concrete and timed. Closing the distance between policy […]
- August 21, 2026
- By Daniel Molloy-Brookes
- Business
The WHO Has Just Published the World’s First Framework for Greener Pharmaceuticals. Here Is Why It Matters.
For the first time, the World Health Organization has set out how regulators worldwide should actively enable pharmaceutical decarbonisation. The framework published in late July 2026 shifts the question from […]
- August 20, 2026
- By Daniel Molloy-Brookes
- Business
Blue Frontier: What the Ocean Is Teaching Life Sciences in 2026
A sea anemone has revealed a way of fighting viruses that runs in the opposite direction to the one in human cells, a peptide from a deep-sea sponge off a […]
- August 19, 2026
- By Daniel Molloy-Brookes
- Business
Beyond Earth’s Orbit: How Space Exploration Is Rewriting Life Sciences in 2026
A cancer drug that once took a 30-minute hospital infusion can now be delivered by injection in as little as one minute, thanks partly to crystals grown on the International […]
- August 18, 2026
- By Daniel Molloy-Brookes
- Business
Ear Buds, Real Data: How AirPods Quietly Became a Life Sciences Tool in 2026
Independent researchers in Ireland have confirmed that AirPods Pro 3 can track heart rate almost as accurately as a hospital-grade chest strap, an audiology team has shown that AirPods Pro […]
- August 17, 2026
- By Daniel Molloy-Brookes
- Business
From the Production Line to the Clinic: How the West Midlands’ Driving Heritage Is Reshaping Life Sciences
A £12.5 million programme is paying automotive suppliers to reinvent themselves as medical technology manufacturers, a University of Warwick spin-out is turning decades of engineering research into a national clinical […]
- August 14, 2026
- By Daniel Molloy-Brookes
- Business
Departures Board: How Travel Became a Life Sciences Laboratory in 2026
A compound tested on jet-lagged mice has cut recovery time nearly in half, wastewater pumped from transatlantic aircraft toilets caught a new coronavirus variant spreading a full month before conventional […]
- August 13, 2026
- By Daniel Molloy-Brookes
- Business
Above the Tree Line: What Hiking and Mountaineering Are Teaching Life Sciences in 2026
A smartwatch tested against a mercury sphygmomanometer at 4,014 metres has just shown exactly where consumer health tech stops being trustworthy, a cargo drone in the Dolomites has cut mountain […]
- August 12, 2026
- By Daniel Molloy-Brookes
- Business
The Genomic Test That Could Spare Thousands of Breast Cancer Patients From Chemotherapy
For decades, one of the most difficult decisions in breast cancer treatment has been knowing who genuinely needs chemotherapy. Chemotherapy can significantly reduce the risk of cancer returning, but the […]
- August 11, 2026
- By Daniel Molloy-Brookes
- Business
UK Biotech Funding Hits a Five-Year High: What Is Driving the Recovery?UK biotech investment has just recorded its strongest quarter in five years.
New figures from the BioIndustry Association (BIA) show that UK biotech companies secured £2.11 billion in equity financing between April and June 2026, including a record £2.05 billion in venture […]
- August 10, 2026
- By Daniel Molloy-Brookes
- Business
The First mRNA Flu Vaccine Has Been Approved. Here Is What That Actually Means.
The FDA cleared Moderna’s mFlusiva on 5 August 2026, making it the first influenza vaccine built on messenger RNA technology to reach the market. The approval completes a turbulent regulatory […]
- August 7, 2026
- By Daniel Molloy-Brookes
- Business
Mental Health in 2026: A Promising Drug Trial, a System Under Strain and a New Risk Nobody Regulated in Time
A magic mushroom compound delivered in a converted community building has just shown real promise against depression that would not respond to anything else, NHS waiting times are edging down […]
- August 6, 2026
- By Daniel Molloy-Brookes
- Business
Relearning How to Move: The Research, Devices and Infrastructure Reshaping Mobility Rehabilitation
A brain implant that lets a paralysed person feel their own footsteps again, a small NHS hospital building its own robotic arm because nothing on the market quite fits and […]
- August 5, 2026
- By Daniel Molloy-Brookes
- Business
Dementia in 2026: Diagnosis Is Racing Ahead of Access
A blood test that can flag Alzheimer’s risk a decade before symptoms appear, a UK trial now recruiting patients through memory clinics to bring that test into the NHS and […]
- August 4, 2026
- By Daniel Molloy-Brookes
- Business
Catching Blood Clots Before They Kill: The Technology Racing to Close an Old Diagnostic Gap
A new PET tracer that can spot clots anywhere in the body from a single scan, a wearable stocking designed to monitor deep vein thrombosis continuously and a UK trial […]
- August 3, 2026
- By Daniel Molloy-Brookes
- Business
Brain Tumours: Why 2026 Is Emerging as a Turning Point for Research and Treatment
A UK government cancer plan naming brain tumours as a national priority, two vaccine trials reporting results that outstrip historical survival figures and a Scottish-born gene therapy heading into its […]
- July 1, 2026
- By Daniel Molloy-Brookes
- Business
Destroying Proteins to Treat Disease: The Drug Class That Is Quietly Rewriting Oncology
A milestone FDA approval and striking Phase 3 data presented this week at ASCO have put targeted protein degradation firmly in the spotlight. After two decades in the making, the […]
- June 24, 2026
- By Daniel Molloy-Brookes
- Business
The Great Rebuild: Why Pharmaceutical Manufacturing Is Being Restructured From the Ground Up
Tariffs, a biologics boom and the industrialisation crisis in cell and gene therapy are converging to force the most significant rethink of pharmaceutical manufacturing in a generation. For most of […]
- June 17, 2026
- By Daniel Molloy-Brookes
- Business
Rewinding the Clock: The Science of Cellular Reprogramming Reaches Human Trials
Two biotechs have now cleared the threshold separating longevity science from regulated medicine. This week’s $435 million raise by NewLimit is the latest signal that epigenetic reprogramming is no longer […]
- June 10, 2026
- By Daniel Molloy-Brookes
- Business
When Your Watch Becomes a Medical Device: The Blurring Boundary Between Consumer Tech and Clinical Care
Smartwatches are detecting heart arrhythmias. Glucose sensors are being worn by people without diabetes. Regulators on both sides of the Atlantic are scrambling to keep pace. The line between wellness […]
- June 3, 2026
- By Daniel Molloy-Brookes
- Business
Pharma’s Carbon Problem: Ambitious Targets, a Stubborn Reality
The life sciences industry emits more than the aviation sector. With net zero deadlines approaching and regulators tightening disclosure rules, the gap between promise and progress has never been more […]
- May 27, 2026
- By Daniel Molloy-Brookes
- Business
FDA Clears AI-Powered Burn Assessment System in Milestone for Emergency Care Diagnostics
The U.S. Food and Drug Administration (FDA) has granted De Novo clearance to Spectral AI’s DeepView System, marking a significant regulatory milestone for artificial intelligence in emergency and wound care. […]
- May 20, 2026
- By Daniel Molloy-Brookes
- Business
Beyond Wegovy: How the Obesity Drug Race Is Reshaping Life Sciences in 2026
The obesity therapeutics market has become one of the most transformative and commercially significant areas in modern life sciences. What began as a breakthrough around GLP-1 receptor agonists has evolved […]
- May 13, 2026
- By Daniel Molloy-Brookes
- Business
The Politics of Life Sciences: Who Really Shapes the Future of Medicine?
Life sciences is no longer just about scientific discovery. It has become a geopolitical battleground, an economic growth strategy and a public trust challenge all at once. Governments, pharmaceutical giants, […]
- May 6, 2026
- By Daniel Molloy-Brookes
- Business
The Role of Precision Fermentation in the Future of Sustainable Healthcare
Innovation in life sciences is increasingly shaped by the need to make healthcare not only more effective but more sustainable. As the industry looks for ways to reduce environmental impact […]
- April 29, 2026
- By Daniel Molloy-Brookes
- Business
The Growing Role of Digital Therapeutics in Modern Healthcare
Healthcare innovation is often associated with breakthrough medicines, advanced diagnostics and cutting-edge medical devices. Yet one of the most significant developments in recent years has emerged through software. Digital therapeutics, […]
- April 22, 2026
- By Daniel Molloy-Brookes
- Business
CRISPR Gene Editing: Advancing Precision Medicine in Modern Healthcare
The development of gene editing technologies has marked a significant shift in the way diseases are understood and potentially treated. Among these innovations, CRISPR has emerged as one of the […]
- April 15, 2026
- By Daniel Molloy-Brookes
- Business
Digital Twins in Healthcare: A New Frontier for Patient-Specific Treatment
The concept of digital twins, long associated with engineering and manufacturing, is beginning to find meaningful application within healthcare. A digital twin refers to a virtual model that accurately reflects […]
- April 8, 2026
- By Daniel Molloy-Brookes
- Business
Climate change and health innovation: how life sciences are responding to a warming world
Climate change is increasingly recognised not only as an environmental crisis, but as a public health challenge. Rising temperatures, extreme weather events and shifting patterns of infectious disease are placing […]
- April 1, 2026
- By Daniel Molloy-Brookes
- Business
Pharmacogenomics: tailoring medicines to your DNA
No two patients respond to medicines in exactly the same way. A drug that works effectively for one person may cause side effects in another or fail to deliver the […]
- April 1, 2026
- By Daniel Molloy-Brookes
- Business
The human microbiome: unlocking the therapeutic potential within
The human body is home to trillions of microorganisms, collectively known as the microbiome. Far from being passive passengers, these bacteria, viruses and fungi play a vital role in digestion, […]
- March 25, 2026
- By Daniel Molloy-Brookes
- Business
Longevity science: extending not just lifespan, but healthspan
Longevity science: extending not just lifespan, but healthspan Populations across the developed world are ageing at an unprecedented rate. In the UK, as in many countries, people are living longer […]
- March 18, 2026
- By Daniel Molloy-Brookes
- Business
CAR-T cell therapy: reprogramming the immune system to fight cancer
Cancer treatment has long relied on surgery, chemotherapy and radiotherapy. In recent years, however, immunotherapy has emerged as a powerful fourth pillar of care. Among the most advanced forms of […]
- March 11, 2026
- By Daniel Molloy-Brookes
- Business
Liquid biopsies: a new era in early cancer detection
Cancer diagnosis has traditionally relied on tissue biopsies, where samples are taken directly from a tumour for analysis. While highly informative, these procedures can be invasive, time-consuming and sometimes difficult […]
- March 4, 2026
- By Daniel Molloy-Brookes
- Business
Wearable biosensors: bringing healthcare closer to the patient
Healthcare has traditionally centred on hospitals and clinics, with diagnosis and monitoring taking place during scheduled appointments. Today, that model is shifting. Wearable biosensors, embedded in smartwatches, patches and other […]
- February 25, 2026
- By Daniel Molloy-Brookes
- Business
Expanding the UK’s capability in advanced therapies
A sector defined by rapid scientific progress Advanced therapies have become one of the most dynamic areas within the UK life sciences sector. Covering cell therapies, gene therapies and tissue […]
- February 18, 2026
- By Daniel Molloy-Brookes
- Business
Building Resilient Supply Chains in Life Sciences
Why supply chains matter in life sciences The life sciences sector relies on complex, interconnected supply chains to deliver medicines, diagnostics and medical technologies to patients. From raw materials and […]
- February 11, 2026
- By Daniel Molloy-Brookes
- Business
The Appendix: Small Organ, Big Learning Curve
By: Amy Deakin I never thought I’d know so much about my own abdomen, incision sites, surgical gas, or elastic waistbands — but here we are. A couple of weeks […]
- January 29, 2026
- By Daniel Molloy-Brookes
- Business
Strengthening real-world evidence in the UK life sciences sector
A growing focus on real world insight Real world evidence has become an increasingly important feature of the UK life sciences landscape. As organisations seek better ways to understand how […]
- January 28, 2026
- By Daniel Molloy-Brookes
- Business
Building the digital foundations for UK life sciences growth
Why digital infrastructure matters now more than ever Digital capability has become a defining factor in the UK’s ambition to strengthen its life sciences sector. While much attention has been […]
- January 21, 2026
- By Daniel Molloy-Brookes
- Business
Strengthening the skills pipeline for the UK’s life sciences future
A renewed focus on sector capability The UK life sciences sector relies on a workforce equipped with the knowledge and technical competence required to support scientific discovery, product development and […]
- January 16, 2026
- By Daniel Molloy-Brookes
- Business
ELSA Diabetes Study
Author: Aimee Richter Type 1 diabetes is a lifelong autoimmune condition where the body mistakenly attacks the insulin producing cells of the pancreas and therefore the ability to regulate sugar. […]
- January 14, 2026
- By Daniel Molloy-Brookes
- Business
The importance of public and private partnerships in life sciences growth
A collaborative foundation for progress Public and private partnerships have become central to the success of the UK life sciences sector. These partnerships draw together the strengths of government, academic […]
- January 7, 2026
- By Daniel Molloy-Brookes
- Business
How the UK’s regulatory landscape is shifting and what it means for innovation
A changing environment for life sciences regulation The UK’s regulatory landscape has entered a period of meaningful change, shaped by the ambition to support innovation while maintaining high standards of […]
- January 2, 2026
- By Daniel Molloy-Brookes
- Business
Opportunities and challenges in digital health adoption
Digital health at a turning point Digital health has moved from the margins of healthcare innovation to the centre of strategic planning across the UK. The growing use of digital […]
- December 24, 2025
- By Daniel Molloy-Brookes
- Business
The role of manufacturing resilience in securing the UK’s life sciences future
Why manufacturing capability matters Manufacturing resilience has become a central theme in discussions about the UK’s long term life sciences strategy. The ability to produce medicines, vaccines and advanced therapies […]
- December 17, 2025
- By Daniel Molloy-Brookes
- Business
How regional innovation clusters support national growth
The rise of regional life sciences ecosystems Regional innovation clusters have become a defining feature of the UK life sciences landscape. These clusters bring together universities, NHS organisations, research institutes […]
- December 10, 2025
- By Daniel Molloy-Brookes
- Business
The evolving skills pipeline in UK life sciences
Understanding the changing shape of the workforce The strength of the UK life sciences sector rests in large part on the quality and depth of its workforce. The sector relies […]
- December 3, 2025
- By Daniel Molloy-Brookes
- Business
What the Chancellor’s Budget Means for the UK Life Sciences Sector
Each year the chancellor’s budget sets the tone for how government intends to steer the wider economy, yet its implications for the life sciences sector often reach far beyond headline […]
- November 25, 2025
- By Daniel Molloy-Brookes
- Business
Life Sciences Week 2026 dates confirmed
National and international focus grows Dates have now been confirmed for Life Sciences Week 2026, the five-day programme of high-profile events uniting senior figures across biotech, medtech, pharma, academia and […]




























































